The 2025 ACVIM Resident Research Abstract Award winners and their recognized works are as follows: Cassidy M. Coats, DVM; ...

cTTP is an inherited condition caused by a deficiency in ADAMTS13, an enzyme critical to blood clotting. Patients can experience a variety of symptoms and severe complications, including ...

Hepatic platelet accumulation in PA-ILI was confirmed in both patients and mice. Deficiency of ADAMTS13 plays a critical role in platelet accumulation in PA-ILI, suggesting that ADAMTS13 could be ...

Low-molecular-weight heparin and recombinant a disintegrin and metalloproteinase with a thrombospondin type I motif member 13 (ADAMTS13) were applied. The necrotic liver area, hepatic platelet ...

Her condition improved following the introduction of glucocorticoids, plasma exchange, and rituximab, with a gradual return to normal values for ADAMTS13 antigen and inhibitory antibodies.

The immune system releases proteins called antibodies that target ADAMTS13, an enzyme that normally prevents your blood from clotting too much. Doctors don’t know what triggers the autoimmune ...

TTP occurs when people have a severe deficiency of the ADAMTS13 enzyme, a protein in the blood that controls blood clotting. Without enough ADAMTS13, excess blood clots form. People may inherit ...

“This approval marks the first treatment specifically indicated to address the root cause of the disease – ADAMTS13 deficiency. Building on our 70-year legacy of innovation in rare blood ...

An ADAMTS13 deficiency can be characterized as either acquired TTP, which typically impacts women who are or were recently pregnant (approximately 1 in every 25,000 pregnancies), or congenital TTP ...

Vice President, Franchise Global Program Leader at Takeda. "With this positive opinion for recombinant ADAMTS13, we are one step closer to offering patients in the EU the first treatment ...